Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Recommendation of "Reduce" by Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) have been assigned a consensus rating of "Reduce" from the six research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.30.

A number of equities research analysts recently issued reports on BHC shares. Wall Street Zen lowered shares of Bausch Health Cos from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. Royal Bank Of Canada upped their target price on shares of Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd.

Insider Buying and Selling

In other Bausch Health Cos news, Director John Paulson purchased 3,564,059 shares of Bausch Health Cos stock in a transaction dated Friday, June 13th. The shares were acquired at an average price of $5.94 per share, with a total value of $21,170,510.46. Following the completion of the transaction, the director owned 32,791,702 shares of the company's stock, valued at $194,782,709.88. This trade represents a 12.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have bought a total of 6,352,667 shares of company stock valued at $35,870,767 over the last 90 days. Corporate insiders own 8.05% of the company's stock.

Institutional Trading of Bausch Health Cos

Several hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in Bausch Health Cos by 1,246.0% in the fourth quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock valued at $160,000 after acquiring an additional 18,366 shares in the last quarter. Vanguard Group Inc. raised its holdings in Bausch Health Cos by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock worth $94,460,000 after purchasing an additional 145,078 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Bausch Health Cos during the fourth quarter worth approximately $180,000. Two Sigma Investments LP raised its holdings in Bausch Health Cos by 688.2% during the fourth quarter. Two Sigma Investments LP now owns 265,461 shares of the company's stock worth $2,140,000 after purchasing an additional 231,781 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Bausch Health Cos by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company's stock worth $10,375,000 after purchasing an additional 14,558 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Cos Stock Down 2.9%

Shares of Bausch Health Cos stock traded down $0.19 during trading hours on Thursday, reaching $6.43. 1,539,470 shares of the company's stock were exchanged, compared to its average volume of 2,576,119. Bausch Health Cos has a 1 year low of $3.96 and a 1 year high of $9.85. The company has a market capitalization of $2.38 billion, a P/E ratio of -58.45 and a beta of 0.41. The business has a fifty day moving average of $5.44 and a two-hundred day moving average of $6.22.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.